Prosecution Insights
Last updated: November 17, 2026

Elion Oncology Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Elion Oncology Inc. manages a company patent portfolio that is currently active within the Biotechnology & Pharmaceuticals technology area. The portfolio presently has 1 pending office action, which represents the entirety of its immediate prosecution requirements. This single action is being handled by LAU, JONATHAN S, who is identified as the busiest examiner for the company. Because LAU, JONATHAN S has 1 busiest examiner pending action, the firm's current legal focus is concentrated on a single point of contact within the patent office.

The organizational structure of the portfolio is centralized, as evidenced by the involvement of only 1 distinct examiner and 1 distinct art unit. This concentration suggests a specific technological focus for Elion Oncology Inc. within the broader Biotechnology & Pharmaceuticals field. For a patent practitioner, having 1 distinct art unit simplifies the landscape, as it requires monitoring the procedural norms of only one specific group. The presence of 1 distinct examiner further streamlines communication, as all current pending matters are subject to the discretion of a single individual. This concentration of 1 pending office action under 1 examiner minimizes the complexity of managing diverse examiner preferences across the portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LAU, JONATHAN S 1 63.8% -17.1%

Top Art Units

Art UnitApps
1693 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18529271 METHOD FOR TREATING CANCER WITH A CHEMOTHERAPEUTIC MODIFIER LAU, JONATHAN S 1693 §103Other Final Rejection — Pending Dec 05, 2023

Managing Elion Oncology Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Elion Oncology Inc. have?

Elion Oncology Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Elion Oncology Inc. applications?

Jonathan S Lau has the most, with 1 of Elion Oncology Inc.'s pending office actions.

What technology area are Elion Oncology Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month